Inventiva (NASDAQ:IVA) Sees Strong Trading Volume – Time to Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw strong trading volume on Monday. Approximately 872,731 shares changed hands during mid-day trading, a decline of 2% from the previous session’s volume of 893,689 shares. The stock last traded at $3.1750 and had previously closed at $3.16.

Wall Street Analysts Forecast Growth

A number of research firms have commented on IVA. Guggenheim raised their target price on shares of Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Wall Street Zen raised Inventiva from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd. Weiss Ratings downgraded Inventiva from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Piper Sandler restated an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Finally, Truist Financial upped their target price on Inventiva from $13.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $15.86.

Inventiva Price Performance

The stock’s fifty day moving average is $4.21 and its 200-day moving average is $4.56.

Inventiva (NASDAQ:IVA) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The firm had revenue of $0.75 million for the quarter. As a group, research analysts expect that Inventiva S.A. Sponsored ADR will post -0.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Inventiva

A number of institutional investors have recently modified their holdings of the company. Platt Investment Counsel LLC acquired a new position in Inventiva in the 3rd quarter valued at about $45,000. Engineers Gate Manager LP raised its stake in Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after buying an additional 43,280 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Inventiva during the 4th quarter worth approximately $603,000. Seven Fleet Capital Management LP acquired a new position in Inventiva in the first quarter valued at $1,111,000. Finally, Eventide Asset Management LLC acquired a new stake in shares of Inventiva in the 4th quarter valued at about $1,155,000. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.